Introduction for Lenvaxen 4 mg:

Lenvaxen 4 Each capsule contains Lenvatinib Mesylate INN equivalent to Lenvatinib 4 mg. Lenvatinib is manufactured By Everest Pharmaceuticals Ltd.

Indications:

Lenvaxen is a kinase inhibitor which is suggested for:
1. Lenvaxen is used to treat patients with locally recurrent or metastatic differentiated thyroid carcinoma (DTC) that is progressing and resistant to radioactive iodine.
2. Renal Cell Carcinoma: Lenvaxen is used in combination with Everolimus to treat individuals with advanced renal cell carcinoma (RCC) after one previous anti-angiogenic therapy.
3. Hepatocellular Carcinoma: Lenvaxen is used as the first-line treatment for patients with unresectable HCC.
4. Endometrial Carcinoma: Lenvaxen, in combination with Pembrolizumab, is indicated for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), who have developed after prior systemic therapy and are not candidates for curative surgery or radiation.

Therapeutic/Drug Class:

Targeted Cancer Therapy.

Pharmacology:

Lenvaxen 4 (Lenvatinib) is a kinase inhibitor that blocks the kinase activity of the VEGF receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvaxen 4 (Lenvatinib)  inhibits other kinases that have been linked to pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, such as fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; platelet-derived growth factor receptor alpha (PDGFR), KIT, and RET. Lenvaxen 4 (Lenvatinib)  also shown antiproliferative action in hepatocellular cancer cell lines that relied on active FGFR signaling while inhibiting FGF-receptor substrate 2 (FRS2) phosphorylation.

Absorption: The time to peak plasma concentration (Tmax) ranged from 1 to 4 hours post-dose. Administration of Lenvaxen 4 (Lenvatinib) with a high-fat meal (about 900 calories, 55% fat, 15% protein, and 30% carbohydrates) had no effect on the extent of absorption, but did reduce the pace of absorption and delay the median Tmax from 2 to 4 hours.

Distribution: In vitro binding of Lenvaxen 4 (Lenvatinib)  to human plasma proteins varied from 98% to 99% at doses of 0.3-30 μg/mL. In vitro, the blood-to-plasma concentration ratio varied between 0.59 and 0.61 at doses ranging from 0.1 to 10 μg/mL.

Metabolism: The primary metabolic routes for Lenvaxen 4 (Lenvatinib)  in humans were found as enzymatic (CYP3A and aldehyde oxidase) and non-enzymatic.

Elimination: Lenvaxen 4 (Lenvatinib)’s terminal elimination half-life was approximately 28 hours.

Dosage and administration of Lenvaxen 4 mg:

For differentiated thyroid carcinoma (DTC): 24 mg orally once daily. The recommended dosage of lenvaxen 4 for renal cell carcinoma (RCC) is 18 mg orally once daily, with everolimus 5 mg orally once daily. Hepatocellular carcinoma (HCC): The recommended dosage is depending on the real body weight. 12 mg of lenvaxen 4 orally once daily for patients weighing more than or equal to 60 kg. 8 mg orally of lenvaxen 4 once daily for patients weighing less than 60 kg. Adjust the recommended daily dose for patients with renal or hepatic impairment.

Interaction:

Lenvaxen 4 mg interacts with drugs that prolong the QT interval. Lenvaxen 4  has been shown to lengthen the QT/QTc interval. Avoid taking Lenvaxen 4 with medicines that have been shown to extend the QT/QTc interval.

Contraindications:

It is not recommended for patients who have a known hypersensitivity to Lenvaxen 4 mg or any other component of the formulation.

Side Effects Of Lenvaxen 4 mg:
Hypertension, cardiac dysfunction, arterial thromboembolic events, hepatotoxicity, renal failure and impairment, proteinuria, diarrhea, fistula formation and gastrointestinal perforation, QT interval prolongation, hypocalcemia, reversible posterior leukoencephalopathy syndrome, hemorrhagic events, impaired thyroid stimulating hormone suppression/thyroid dysfunction, and wound healing complications.

Pregnancy and Lactation:

 Lenvaxen’s mechanism of action may harm embryos and fetuses when provided to pregnant women. So pregnant women should be made aware of the fetal risk.
Lactation: It is unclear whether Lenvaxen is present in human milk. Because of the risk of serious side effects in breastfed infants, women should quit breastfeeding throughout Lenvaxen treatment and for at least one week after the last dosage.

Overdose Effects of Lenvaxen 4 mg:
Due to its strong plasma protein binding, Lenvaxen 4 mg is not predicted to be dialyzable. A patient can die due to multiorgan malfunction after receiving a single dose of Lenvatinib 120 mg orally.

Storage Conditions:

Lanvaxen 4mg should be kept between 25°C and 30°C at room temperature. When a medication is no longer needed or has expired, dispose of it safely. Protect  Lanvaxen 4mg from sunlight and humidity. Keep  Lanvaxen 4mg and all medicines out of the reach of children.

See more Oncology medicine visit our Shop